Results 91 to 100 of about 693 (177)

Investing in prostate cancer survivorship. [PDF]

Can Urol Assoc J
Nguyen DD, Wallis CJD.
europepmc   +1 more source

Immunophenotypic changes following menin inhibition in acute myeloid leukemia. [PDF]

Leukemia
Loghavi S, Farhat A, Jamison TJ, El Hajjar G, Bataller A, Wang SA, Wang W, Tang G, Quesada AE, Bazinet A, Cuglievan B, DiNardo CD, Montalban-Bravo G, Takahashi K, Short NJ, Abbas HA, Kadia T, Ravandi F, Daver N, Jabbour E, Borthakur G, Andreeff M, Medeiros LJ, Kantarjian HM, Issa GC.   +24 more
europepmc   +1 more source

Gene prediction of aging-related diseases based on DNN and Mashup. [PDF]

BMC Bioinformatics, 2021
Ye J, Wang S, Yang X, Tang X.
europepmc   +1 more source

Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102). [PDF]

JCO Oncol Adv
Chen YW, Bobek O, Heller G, Berg S, Tan A, Zhao SG, Galsky M, Rosenberg J, Beltran H, McKay RR.   +9 more
europepmc   +1 more source

Gender Disparities in Citations and Altmetric Attention Score in Oncology. [PDF]

JCO Oncol Pract
Campbell RA, Helstrom E, Chew L, Eapen R, Plimack E, Correa A, Kutikov A, Abbosh P, Calaway A, Nizam A, Gupta S, Psutka SP, Barata P, Dizman N, Sindhani M, Weight CJ, Bukavina L.   +16 more
europepmc   +1 more source

Integrating multimodal data through interpretable heterogeneous ensembles. [PDF]

Bioinform Adv, 2022
Li YC, Wang L, Law JN, Murali TM, Pandey G.   +4 more
europepmc   +1 more source

Direct-to-Participant Enrollment in a Virtual Trial: Lessons Learned From the Heartline Study. [PDF]

JACC Adv
Hills MT, Korjian S, Chi G, Natale A, Saxon L, Ferdinand KC, Kwaku KF, Brancato S, Hughes A, Baca-Motes K, Steinhubl SR, Wessler J, Goldberg N, Asthana A, Shute K, Applebaum J, Doran K, Nikolovski J, Kaul S, Wentworth D, Damaraju CV, Tavakoli C, Patel M, Curtis AB, Spertus JA, Gibson CM, Heartline Executive Committee and Steering Committee.   +26 more
europepmc   +1 more source

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria. [PDF]

ESMO Open
Apolo AB, Bellmunt J, Cordes L, Gupta S, Powles T, Rosenberg JE, Van Der Heijden MS.   +6 more
europepmc   +1 more source

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients. [PDF]

Blood Cancer J
Firestone RS, Simhal AK, Akhlaghi T, Oh JH, McAvoy D, Maclachlan KH, Garces JJ, Mailankody S, Hassoun H, Shah UA, Korde N, Tan CR, Rajeeve S, Hashmi H, Lesokhin AM, Hosszu K, Maura F, Deasy JO, Usmani SZ, Hultcrantz M.   +19 more
europepmc   +1 more source

ICoN: integration using co-attention across biological networks. [PDF]

Bioinform Adv
Tasnina N, Murali TM.
europepmc   +1 more source